TScan Therapeutics, Inc. Income Statement
TCRX|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
TScan Therapeutics, Inc. reported $3M in revenue and $127M in net loss for FY2025. Revenue has grown at a 26.9% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $21.0M | $13.5M | $10.1M | $1.1M |
| SG&A Expense | $30.3M | $26.4M | $20.4M | $13.8M | $6.7M |
| R&D Expense | $107.3M | $88.2M | $59.8M | $45.0M | $20.6M |
| Operating Income | -$134.8M | -$93.5M | -$66.6M | -$48.6M | -$26.2M |
| Interest Expense | $3.7M | $3.8M | $1.2M | $1.2M | - |
| Income Tax | $0 | - | - | - | - |
| Net Income | -$127.5M | -$89.2M | -$66.2M | -$48.6M | -$26.1M |
| EPS (Basic) | -$1.14 | -$1.36 | -$2.75 | -$4.17 | - |
| EPS (Diluted) | -$1.14 | -$1.36 | -$2.75 | -$4.17 | -$28.52 |
| Shares Outstanding | 112.0M | 65.6M | 24.0M | 11.7M | 916.0K |
| Operating Margin | -4787.7% | -444.0% | -492.3% | -479.6% | -2417.8% |
| Profit Margin | -4527.7% | -423.9% | -489.3% | -479.5% | -2408.0% |